Compare CDNA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | MDXG |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.2M | 1.0B |
| IPO Year | 2014 | N/A |
| Metric | CDNA | MDXG |
|---|---|---|
| Price | $20.58 | $7.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $26.00 | $12.00 |
| AVG Volume (30 Days) | ★ 778.5K | 755.0K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.22 | 0.27 |
| Revenue | $357,998,000.00 | ★ $393,442,000.00 |
| Revenue This Year | $14.11 | $19.13 |
| Revenue Next Year | $12.00 | $2.11 |
| P/E Ratio | ★ $16.30 | $26.86 |
| Revenue Growth | 14.46 | ★ 14.77 |
| 52 Week Low | $10.96 | $5.79 |
| 52 Week High | $25.95 | $9.71 |
| Indicator | CDNA | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 71.98 | 56.44 |
| Support Level | $18.36 | $6.62 |
| Resistance Level | $19.95 | $7.06 |
| Average True Range (ATR) | 0.86 | 0.23 |
| MACD | 0.19 | 0.05 |
| Stochastic Oscillator | 99.42 | 91.11 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.